

# Validation data for Anti-hTIGIT-hIgG1NQ

<https://www.invivogen.com/nongylco-anti-htigit-mab>


For research use only

Version 19J24-ED

Anti-hTIGIT-hIgG1NQ is a recombinant monoclonal antibody (mAb) featuring a variable region that recognizes human TIGIT and the non-glycosylated constant region of the engineered human IgG1 isotype (hIgG1NQ). TIGIT is an important immune checkpoint, specifically expressed on natural killer (NK) cells, and range of T cell subsets. Upon binding to its ligand, TIGIT directly reduces NK cytotoxicity as well as T cell activation and proliferation. The binding of Anti-hTIGIT-hIgG1NQ has been validated using engineered TIGIT-expressing Raji cells (Figure 1).

## Binding of Anti-hTIGIT-hIgG1NQ to target cells

The binding of Anti-hTIGIT-hIgG1NQ to cell-expressed TIGIT has been validated using engineered TIGIT-expressing Raji cells (Raji-hTIGIT) compared to Raji-null cells, which do not express TIGIT. A clear shift to the right of the fluorescence peak is noted when Anti-hTIGIT-hIgG1NQ is incubated with Raji-hTIGIT (right) and not Raji-null (left) cells, indicating strong and specific binding.



**Figure 1:** Anti-hTIGIT-hIgG1NQ (2 µg) was added to Raji-null (negative control) and Raji-hTIGIT cells (500 000 cells/ml) and incubated at room temperature for 30 minutes. Following this, a secondary antibody, PE, was added and incubated again at room temperature for 30 minutes. The binding affinity was then measured using flow cytometry.

### TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873

InvivoGen USA (International): +1 (858) 457-5873

InvivoGen Europe: +33 (0) 5-62-71-69-39

InvivoGen Hong Kong: +852 3-622-34-80

E-mail: [info@invivogen.com](mailto:info@invivogen.com)